close
MENU
Hot Topic Long reads
Hot Topic Long reads
Tech & Innovation
5 mins to read

GlycoSyn ‘bringing home the bacon’ in science commercialisation

Callaghan Innovation’s chemist shop has collaborated with more than 100 companies worldwide to develop new drug ingredients.

The GlycoSyn lab at Gracefield.

Key points
  • What’s at stake: Callaghan Innovation business unit GlycoSyn has worked with more than 100 drug companies worldwide to develop ingredients that are the key constituents of vaccines, antivirals, and rare disease therapies.
  • Background: GlycoSyn was born in 2003 out of the former IRL’s Carbohydrate Chemistry Team led by Professors Richard Furneaux and Peter Tyler – who later shifted to the Ferrier Institute. 
  • Main players: GlycoSyn, Callaghan Innovation, the Ferrier Institute at Victoria University.

Molybdenum Cofactor Deficiency (MoCD) is a rare, genetic metabolic disorder that typically presents in the first few days of someone’s life. It causes seizures, brain injury, and death.

MoCD patients can’t produce a substance known as cyclic pyrantoperin monophosphate. In 2010, New Zealand

Want to read more? It's easy.

Choose your best value subscription option

Student

Exclusive offer for uni students studying at a New Zealand university (valued at $499).
Individual
Group membership
NBR Marketplace

Yearly Premium Online Subscription

NZ$499.00 / yearly

Monthly Premium Online Subscription

NZ$44.95 / monthly

Smartphone Only Subscription

NZ$24.95 / monthly

Premium Group Membership 10 Users

NZ$385+GST / monthly

$38.5 per user - Pay by monthly credit card debit

Premium Group Membership 20 Users

NZ$660+GST / monthly

$33 per user - Pay by monthly credit card debit

Premium Group Membership 50 Users

NZ$1375+GST / monthly

$27.5 per user - Pay by monthly credit card debit

Premium Group Membership 100 Users

NZ$2100+GST / monthly

$21 per user - Pay by monthly credit card debit

Yearly Premium Online Subscription + NBR Marketplace

NZ$499.00 / yearly

Already have an account? Login
Fiona Rotherham Fri, 24 Jan 2025
Contact the Writer: fiona@nbr.co.nz
News tip? Question? Typo? Let us know: editor@nbr.co.nz
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
Key points
  • What’s at stake: Callaghan Innovation business unit GlycoSyn has worked with more than 100 drug companies worldwide to develop ingredients that are the key constituents of vaccines, antivirals, and rare disease therapies.
  • Background: GlycoSyn was born in 2003 out of the former IRL’s Carbohydrate Chemistry Team led by Professors Richard Furneaux and Peter Tyler – who later shifted to the Ferrier Institute. 
  • Main players: GlycoSyn, Callaghan Innovation, the Ferrier Institute at Victoria University.
GlycoSyn ‘bringing home the bacon’ in science commercialisation
Tech & Innovation,
107438
true